相关实验视频

Updated: Jul 4, 2025

Isolation of Macrophage Subsets and Stromal Cells from Human and Mouse Myocardial Specimens

Isolation of Macrophage Subsets and Stromal Cells from Human and Mouse Myocardial Specimens

Published on: December 17, 2019

矿物质皮质类受体促进心脏巨细胞的炎症

Daniela Fraccarollo¹, Robert Geffers², Paolo Galuppo³

¹Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str.1 30625, Hannover, Germany. fraccarollo.daniela@mh-hannover.de.

Basic research in cardiology

|February 8, 2024

概括

针对心脏巨细胞中的矿物质皮质类受体 (MR),可以对抗与衰老相关的炎症和纤维化. 这项研究揭示了MRMR.

科学领域:

心血管生物学心血管生物学
免疫学免疫学免疫学
衰老研究研究衰老研究

背景情况:

衰老的特点是炎症,一种由巨细胞驱动的促炎状态,有助于与年龄相关的疾病.
巨细胞中的矿物质皮质体受体 (MR) 调节炎症和纤维化,但其在心脏衰老中的作用尚不清楚.

研究的目的:

研究巨细胞特异性MR在调节衰老期间心脏炎症和纤维化中的作用.
阐明巨细胞MR影响心脏衰老和功能障碍的机制.

主要方法:

从年轻和老年小鼠的心脏巨细胞和纤维细胞的转录组概况.
分析巨细胞表型及其与纤维细胞的相互作用.
使用肌肉细胞受限MR缺乏的小鼠模型.

主要成果:

骨髓细胞特异性MR缺陷阻止了亲炎性巨细胞的分化,并调节了老年巨细胞的炎症/新陈代谢途径.
巨细胞MR缺陷减少了心脏纤维细胞中的炎症和纤维化相关途径.
巨细胞的MR缺陷减少了TIMD4阴性巨细胞群体,并防止心脏炎症,纤维化和功能障碍.

结论:

巨MR是心脏炎症和与年龄相关的纤维化重塑的关键调解者.
向巨细胞MR提供了一种潜在的治疗策略,以减轻与年龄有关的心脏功能障碍.

关键词:

衰老的衰老衰老的衰老纤维化纤维化纤维化炎症炎症是一种炎症.巨细胞是一个巨细胞.矿物甲类皮质体受体受体

更多相关视频

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

Analyzing Ex Vivo Metabolic Flux in Splenic and Cardiac Macrophages and Bone Marrow Monocytes

Analyzing Ex Vivo Metabolic Flux in Splenic and Cardiac Macrophages and Bone Marrow Monocytes

Published on: March 28, 2025

相关概念视频

Inflammation

Inflammation

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...